ArticleEmerging infectious diseases2026
Emergence of New Delhi Metallo-β-Lactamase 14-Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FTIR typing of the emerging NDM-14-producingJournal of clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of a high-risk New Delhi metallo-β-lactamase 14-producing Klebsiella pneumoniae sequence type 147 clone is of public health concern because of its rapid international spread. We report cross-border emergence and rapid dissemination of that clone in the Canary Islands, Spain, during 2023-2025. We analyzed 30 isolates recovered during 2023 in detail by reviewing clinical and epidemiologic data, conducting whole-genome sequencing to assess clonal relatedness and analyze resistomes, and performing antimicrobial susceptibility testing of novel therapeutic options through reference broth microdilution. The isolates formed a well-defined cluster, with minimal genomic distance and identical resistomes, confirming the local outbreak. Those clones were also closely related to other international New Delhi metallo-β-lactamase 14-producing K. pneumoniae sequence type 147 isolates, supporting the ongoing cross-border expansion of that clone. Aztreonam/avibactam was the most active therapeutic option (MICs <0.125 mg/L). Our findings highlight the need for close monitoring to prevent further dissemination of this clone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.